Group 1 - The core viewpoint of the article highlights the strong market position and financial performance of WuXi Biologics, a leading global biopharmaceutical service provider [1][2][3] - As of August 14, WuXi Biologics' stock price increased by 2.01%, reaching HKD 31.42 per share, with a trading volume of HKD 3.88 billion [1] - The company held a 48% market share in China's biopharmaceutical R&D market in 2016 and has established partnerships with 12 out of the top 20 global pharmaceutical companies [1] Group 2 - For the fiscal year ending 2024, WuXi Biologics reported total revenue of HKD 18.675 billion and a net profit of HKD 3.356 billion [2] - The company is set to disclose its mid-year report for the fiscal year 2025 on August 19 [2]
药明生物(02269)上涨2.01%，报31.42元/股